Sabra Health Care REIT posts Q4 2025 net income of USD 27.23 million; same property managed senior housing Cash NOI up 12.6 percent

Reuters
02/13
Sabra Health Care REIT posts Q4 2025 net income of USD 27.23 million; same property managed senior housing Cash NOI up 12.6 percent

Sabra Health Care REIT Inc. reported its fourth quarter (Q4) 2025 earnings, posting net income per diluted common share of USD 0.11. Funds from Operations (FFO) and Normalized FFO per diluted common share were both USD 0.36, while Adjusted Funds from Operations (AFFO) per diluted common share stood at USD 0.37 and Normalized AFFO at USD 0.38 for the period. Net income attributable to shareholders for Q4 2025 was USD 27.23 million. For the full year (FY) 2025, net income attributable to shareholders reached USD 155.61 million, with net income per diluted common share at USD 0.64. Key business highlights for the quarter included a 12.6% year-over-year increase in same property managed senior housing Cash NOI for Q4 2025. The average quarterly year-over-year increase for 2025 was 15.0%, which includes the impact of stabilized facilities formerly operated by Holiday. EBITDARM coverage ratios for the quarter were as follows: Skilled Nursing/Transitional Care at 2.38x, Senior Housing - Leased at 1.52x, and Behavioral Health, Specialty Hospitals and Other at 3.99x.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sabra Health Care REIT Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212530499) on February 12, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10